Black Diamond Therapeutics share price logo

Black Diamond Therapeutics

NASDAQ: BDTX

$2.06

-0.04

(-1.67%)

Live

as on

Black Diamond Therapeutics Stock Performance

as on September 2, 2026 at 5:49 am IST

  • Day's Low

    Day's High

    $2.02
    $2.10
    downward going graph

    1.94%

    Downside

    1.94%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.60
    $4.94
    downward going graph

    22.33%

    Downside

    139.81%

    Upside

    downward going graph

Black Diamond Therapeutics share price movements today

Previous Close
$2.10
Open
$2.09
Volume
1.3M
Market Cap
$128.1M
Day's Low - High
$2.02 - $2.10
52 Week Low - High
$1.60 - $4.94

Black Diamond Therapeutics Historical Returns

1 Month Return
+ 31.95 %
3 Month Return
+ 0.45 %
1 Year Return
-18.91 %
3 Year Return
-33.83 %
5 Year Return
-77.92 %

Black Diamond Therapeutics Stock Fundamentals & Key Indicators

Check Black Diamond Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$128.1M

EPS (TTM)

-0.5667

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-44.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-37.22%

Black Diamond Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Black Diamond Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$128.1M-77.92%NA0.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$137.2B170.45%31.9286.04%NA
BUY$55.1B-63.37%-7.98-12.57%NA
BUY$85.8B17.94%19.984.86%0.44%

Stock Returns calculator for Black Diamond Therapeutics Stock including INR - Dollar returns

The Black Diamond Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Black Diamond Therapeutics investment value today

Current value as on today

₹80,816

Returns

-₹19,184

(-19.18%)

Returns from Black Diamond Therapeutics Stock

-₹25,091 (-25.09%)

Dollar Impact

₹5,907 (+5.91%)

Analyst Recommendation on Black Diamond Therapeutics Stock

Based on 7 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 7 analysts, 100% of analysts recommend a 'BUY' rating for Black Diamond Therapeutics. Average target price of $10

Black Diamond Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Black Diamond Therapeutics.

What analysts predicted

79.4%UPSIDE

Target Price

$10

Current Price

$2.06

Analyzed by

7 Analysts

Target

$10.00

Black Diamond Therapeutics target price $10, a slight upside of 79.4% compared to current price of $2.06. According to 7 analysts rating.

Indian Investors' Interest in Black Diamond Therapeutics Stock

Search interest for Black Diamond Therapeutics Stock has increased by 11% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:11% versus previous 30 day period

Black Diamond Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
0
70
-
-
-
-
-
Gross Profit
0
0
0
0
70
0
-
0
0
-
Operating Income
-20
-22
-18
-18
54
-13
-10
-17
-11
-12
EBITDA
-18
-19
-15
-15
56
-10
-8
-10
-9
-13
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-18
-19
-15
-15
56
-10
-8
-15
-9
-9
Income Tax Expense
0
-
0
-
-
-
-
-
-
-
Net Income
-18
-19
-15
-15
56
-10
-8
-15
-9
-9
Net Profit Margin
0.00%
0.00%
0.00%
-3097.87%
80.77%
0.00%
0.00%
0.00%
0.00%
0.00%

Black Diamond Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
70
Gross Profit
0
0
0
0
-2
-3
0
0
69
Operating Income
-4
-8
-8
-69
-126
-92
-86
-78
19
EBITDA
-4
-8
-29
-66
-125
-90
-82
-69
22
Interest Expense
0
-
-
0
1
3
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-4
-8
-35
-67
-125
-91
-82
-69
22
Income Tax Expense
0
0
5
-1
-2
-4
-
-
-
Net Income
-4
-8
-35
-67
-125
-91
-82
-69
22
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
31.95%

Black Diamond Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-19
-15
-15
56
-10
-8
-15
-9
-9
Operating Cash Flow
-14
-11
-15
53
-9
-7
-6
-10
-7
Investing Cash Flow
0
2
27
8
-59
8
-2
19
-3
Financing Cash Flow
21
0
0
0
0
0
0
0
0
Change in Cash
7
-9
13
61
-68
0
-9
9
-10

Black Diamond Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-8
-35
-67
-125
-91
-82
-69
22
Operating Cash Flow
-8
-24
-52
-100
-85
-66
-62
29
Investing Cash Flow
0
0
-281
130
53
16
16
-44
Financing Cash Flow
52
127
214
0
0
71
25
0
Change in Cash
43
103
-118
31
-31
21
-19
-15

Mutual Funds that own Black Diamond Therapeutics Stock

Check out the Mutual Funds with significant holdings in Black Diamond Therapeutics.

Funds
Holdings
Shares Held
T. ROWE PRICE SMALL-CAP STOCK FUND, INC.
4.606216%
2646444
T. ROWE PRICE SMALL-CAP VALUE FUND, INC.
3.707417%
2130050
VANGUARD INDEX FUNDS
3.120247%
1792699
T. Rowe Price Equity Funds, Inc.
2.430736%
1396549
DFA INVESTMENT DIMENSIONS GROUP INC
1.051978%
604401

Global Institutional Holdings in Black Diamond Therapeutics

Funds
Holdings
iShares
4.75%
Vanguard
4.14%
Fidelity
1.03%
Dimensional
0.66%
Bridgeway
0.61%

Black Diamond Therapeutics News & Key Events

  • img

    Today's Timeline - 03 December

    Wed, 08:33 PM

    -

    Black Diamond shares drop 28% after reporting Phase 2 data for Silevertinib in NSCLC and plans for GBM trial.

Insights on Black Diamond Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, BDTX stock has moved up by 24.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 24.7% return, outperforming this stock by 65.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 482.6% return, outperforming this stock by 506.2%

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
OrganisationBlack Diamond Therapeutics
Headquarters245 First Street, Cambridge, MA, United States, 02142
IndustryBiotechnology
CEODr. Mark A. Velleca M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Black Diamond Therapeutics

Name

Title

Dr. Mark A. Velleca M.D., Ph.D.

CEO, President & Chairman

Mr. Brent Hatzis-Schoch Esq., J.D.

COO & General Counsel

Dr. Sergey Yurasov M.D., Ph.D.

Chief Medical Officer

Dr. Elizabeth Buck Ph.D.

Co-Founder & Chief Scientific Officer

Ms. Erika Jones

Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller

Ms. Melanie Morrison

Chief Development Officer

FAQs

What is Black Diamond Therapeutics share price today?

Black Diamond Therapeutics share price today is $2.06 as on . Black Diamond Therapeutics share today touched a day high of $2.10 and a low of $2.02.

What is the 52 week high and 52 week low for Black Diamond Therapeutics share?

Black Diamond Therapeutics share touched a 52 week high of $4.94 on and a 52 week low of $1.60 on . Black Diamond Therapeutics stock price today i.e. is trending at $2.06,which is 58.30% down from its 52 week high and 28.75% up from its 52 week low.

What is Black Diamond Therapeutics's market capitalisation today?

Black Diamond Therapeutics market capitalisation is $0.00T as on .

How to invest in Black Diamond Therapeutics Stock (BDTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Black Diamond Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Black Diamond Therapeutics Shares that will get you 0.7282 shares as per Black Diamond Therapeutics share price of $2.06 per share as on September 2, 2026 at 12:19 am IST.

What is the minimum amount required to buy Black Diamond Therapeutics Stock (BDTX) from India?

Indian investors can start investing in Black Diamond Therapeutics (BDTX) shares with as little as ₹94.94 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Black Diamond Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Black Diamond Therapeutics share’s latest price of $2.06 as on September 2, 2026 at 12:19 am IST, you will get 4.8544 shares of Black Diamond Therapeutics. Learn more about fractional shares .

What are the returns that Black Diamond Therapeutics has given to Indian investors in the last 5 years?

Black Diamond Therapeutics stock has given -77.92% share price returns and 30.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?